Vivacelle Bio Exec to Present Clinical Data at BIO International 2024

Vivacelle Bio, a late-stage biopharmaceutical company based in Kansas City, Missouri, is making significant strides in developing life-saving treatments for shock and trauma conditions. Leading its pipeline is VBI-S, a Phase 3-ready asset aimed at treating hypotension and hypovolemia in septic shock patients, and VBI-1, which is in Phase 2 and focuses on hemorrhagic shock.

On May 31, 2024, Vivacelle announced that Dr. Cuthbert Simpkins, President and Chief Innovation Officer, has been invited by the National Institutes of Health (NIH) to showcase the company’s clinical programs at the 2024 BIO International Convention in San Diego. Dr. Simpkins will deliver two presentations titled "Multiple Clinical Problems Solved Using Phospholipid Nanoparticles," detailing the company's advanced clinical initiatives. These presentations will take place on June 3 and June 4, providing a platform for engaging with potential pharmaceutical partners and investors.

Vivacelle's VBI-S, which utilizes patented phospholipid nanoparticle technology, has demonstrated remarkable efficacy in clinical trials. This technology works by redistributing nitric oxide to elevate blood pressure in patients suffering from hypovolemic septic shock—a condition that claims millions of lives worldwide each year. A Phase 2 trial of VBI-S showed 100% efficacy, successfully elevating blood pressure in patients who were non-responsive to other treatments.

Harven DeShield, CEO of Vivacelle, expressed enthusiasm about presenting the company's advancements at the BIO Convention. He emphasized the significant clinical milestones achieved over the past year, including the impressive results from the VBI-S Phase 2 trial and a pivotal study published in The Lancet eClinicalMedicine. DeShield is optimistic that these developments will attract interest from pharmaceutical and commercial partners, helping to initiate a multicenter Phase 3 study of VBI-S soon.

Dr. Simpkins' presentations are expected to underscore the innovative and effective nature of Vivacelle's phospholipid nanoparticle technology platform. This platform is particularly significant given that nearly 2 million people in the United States develop sepsis annually, and current treatments fall short of addressing the condition adequately. Clinical data indicates that VBI-S not only improves blood pressure but also reverses organ failure, which is crucial in reducing sepsis-related mortality. The product's potential has garnered ongoing support from the US Department of Defense and the NIH, highlighting its promising therapeutic impact.

Vivacelle's Phase 2a clinical trial and the subsequent multicenter Phase 3 study of VBI-S are funded by the Naval Medical Research Command (NMRC) through the Naval Advanced Medical Development (NAMD) program, facilitated by the Medical Technology Enterprise Consortium (MTEC). MTEC, a biomedical technology consortium, collaborates under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) to serve military and civilian medical needs.

Vivacelle Bio continues to advance its mission of developing treatments for shock and trauma, supported by both venture capital and substantial backing from governmental agencies. Through their innovative approach and dedicated research, Vivacelle is poised to make a significant impact in the medical field, potentially saving countless lives affected by septic and hemorrhagic shock conditions.